Found: 83
Select item for more details and to access through your institution.
Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
- Published in:
- Prostate, 1997, v. 30, n. 2, p. 73, doi. 10.1002/(SICI)1097-0045(19970201)30:2<73::AID-PROS1>3.0.CO;2-L
- By:
- Publication type:
- Article
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 3, p. 439, doi. 10.1007/s00432-016-2318-x
- By:
- Publication type:
- Article
Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Spindle Cell Squamous Carcinoma During BRAF Inhibitor Therapy for Advanced Melanoma: An Aggressive Secondary Neoplasm of Undetermined Biologic Potential.
- Published in:
- JAMA Dermatology, 2014, v. 150, n. 5, p. 575, doi. 10.1001/jamadermatol.2013.7784
- By:
- Publication type:
- Article
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
- Published in:
- BJU International, 2005, v. 96, n. 3, p. 286, doi. 10.1111/j.1464-410X.2005.05616.x
- By:
- Publication type:
- Article
Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
- Published in:
- American Journal of Clinical Dermatology, 2018, v. 19, n. 5, p. 657, doi. 10.1007/s40257-018-0359-4
- By:
- Publication type:
- Article
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00896-0
- By:
- Publication type:
- Article
Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.
- Published in:
- Current Oncology Reports, 2016, v. 18, n. 1, p. 1, doi. 10.1007/s11912-015-0485-6
- By:
- Publication type:
- Article
Biological drug duo delivers one-two tumor punch.
- Published in:
- Nature Medicine, 2003, v. 9, n. 6, p. 649, doi. 10.1038/nm0603-649
- By:
- Publication type:
- Article
Severe eosinophilia and hepatocellular carcinoma: An unusual association.
- Published in:
- Diagnostic Cytopathology, 1995, v. 13, n. 2, p. 151, doi. 10.1002/dc.2840130215
- By:
- Publication type:
- Article
Oral health in oncology: impact of immunotherapy.
- Published in:
- 2015
- By:
- Publication type:
- Letter
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04100-y
- By:
- Publication type:
- Article
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
- Published in:
- 2022
- By:
- Publication type:
- journal article
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 1, p. 47, doi. 10.1007/s10637-016-0391-2
- By:
- Publication type:
- Article
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 159, doi. 10.1007/s10637-014-0167-5
- By:
- Publication type:
- Article
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials.
- Published in:
- PLoS ONE, 2012, v. 7, n. 4, p. 1, doi. 10.1371/journal.pone.0035309
- By:
- Publication type:
- Article
B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma.
- Published in:
- Current Oncology Reports, 2010, v. 12, n. 3, p. 146, doi. 10.1007/s11912-010-0095-2
- By:
- Publication type:
- Article
Inside life of melanoma cell signaling, molecular insights, and therapeutic targets.
- Published in:
- Current Oncology Reports, 2009, v. 11, n. 5, p. 405, doi. 10.1007/s11912-009-0054-y
- By:
- Publication type:
- Article
Combination Immunotherapy: An Emerging Paradigm in Cancer Therapeutics.
- Published in:
- Oncology (08909091), 2015, v. 29, n. 12, p. 1005
- By:
- Publication type:
- Article
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 9, p. 1033, doi. 10.1007/s00262-005-0090-x
- By:
- Publication type:
- Article
Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2002, v. 51, n. 5, p. 263, doi. 10.1007/s00262-002-0281-7
- By:
- Publication type:
- Article
CORRESPONDENCE.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Sunlight and Reduced Risk of Cancer: Is The Real Story Vitamin D?
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 3, p. 161, doi. 10.1093/jnci/dji047
- By:
- Publication type:
- Article
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. 1, doi. 10.3389/fimmu.2020.01185
- By:
- Publication type:
- Article
CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. 1, doi. 10.1038/s41467-018-08123-8
- By:
- Publication type:
- Article
Endocrine side effects of immune checkpoint inhibitors.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1157805
- By:
- Publication type:
- Article
Immune Assessment Today: Optimizing and Standardizing Efforts to Monitor Immune Responses in Cancer and Beyond.
- Published in:
- Cancers, 2024, v. 16, n. 3, p. 475, doi. 10.3390/cancers16030475
- By:
- Publication type:
- Article
New Approaches to Targeted Therapy in Melanoma.
- Published in:
- Cancers, 2023, v. 15, n. 12, p. 3224, doi. 10.3390/cancers15123224
- By:
- Publication type:
- Article
The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape.
- Published in:
- Cancers, 2021, v. 13, n. 13, p. 3281, doi. 10.3390/cancers13133281
- By:
- Publication type:
- Article
Identifying treatment options for BRAF<sup>V600</sup> wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.
- Published in:
- PLoS ONE, 2021, v. 16, n. 4, p. 1, doi. 10.1371/journal.pone.0248097
- By:
- Publication type:
- Article
Kidney Cancer: Recent Advances in Diagnosis and Management.
- Published in:
- AUANews, 2008, v. 13, p. 7
- By:
- Publication type:
- Article
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.
- Published in:
- 1990
- By:
- Publication type:
- journal article
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 5, p. 1958, doi. 10.1007/s10637-011-9753-y
- By:
- Publication type:
- Article
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
- Published in:
- Nature, 2010, v. 468, n. 7326, p. 973, doi. 10.1038/nature09626
- By:
- Publication type:
- Article
CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 8, p. 1904, doi. 10.1002/cam4.1140
- By:
- Publication type:
- Article
Nivolumab in melanoma: latest evidence and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2015, v. 7, n. 2, p. 97, doi. 10.1177/1758834014567469
- By:
- Publication type:
- Article
Update on the Targeted Therapy of Melanoma.
- Published in:
- Current Treatment Options in Oncology, 2013, v. 14, n. 2, p. 280, doi. 10.1007/s11864-013-0226-8
- By:
- Publication type:
- Article
Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanomaPresented in part as a poster (abstract 2865) at the Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois, May 31–June 3, 2003.: Significant toxicity with no clinical efficacy
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 9, p. 2005
- By:
- Publication type:
- Article
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Impact of MET expression on outcome in BRAF<sup>V600E/K</sup> advanced melanoma.
- Published in:
- Histopathology, 2013, v. 63, n. 3, p. 351, doi. 10.1111/his.12169
- By:
- Publication type:
- Article
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
- Published in:
- Nature Communications, 2016, v. 7, n. 1, p. 10582, doi. 10.1038/ncomms10582
- By:
- Publication type:
- Article
The Human Vaccines Project: A roadmap for cancer vaccine development.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 334, p. 1, doi. 10.1126/scitranslmed.aaf0685
- By:
- Publication type:
- Article
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Improved methods for RNAseq-based alternative splicing analysis.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-89938-2
- By:
- Publication type:
- Article
The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00200
- By:
- Publication type:
- Article
Adverse Events Associated With Immune Checkpoint Inhibitors-Reply.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Immune Checkpoint Inhibitor Toxicity in 2018.
- Published in:
- 2018
- By:
- Publication type:
- journal article
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
- Published in:
- Nature, 2011, v. 480, n. 7377, p. 387, doi. 10.1038/nature10662
- By:
- Publication type:
- Article
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 5, p. 639, doi. 10.1007/s11523-023-00987-1
- By:
- Publication type:
- Article